Category: FDA New Drug Pipeline and R&D AstraZeneca India China and Asian Pharma Pharmaceutical Patents and Intellectual Property Biotechnology and biopharmaceuticals Pharmaceutical Industry CEOs medical research drug development orphan drugs Obama R&d Gephardt
Submitted by pharmamanufacturing on Thu, 04/16/2009 - 10:08
I spent yesterday afternoon at the Forum for Medical Innovation in downtown Chicago, hosted by the Council for American Medical Innovation and moderated by former U.S. House of Representatives majority leader Dick Gephardt. The event also featured AstraZeneca CEO David Brennan as a guest speaker. [img_assist|nid=1172|title=David Brennan|desc=|link=none|align=right|width=128|height=86]
Category: Process Analytical Technologies The Pharma Industry New Drug Pipeline and R&D Pharmaceutical Patents and Intellectual Property Generic Drugs Environmental issues and green pharma Girish Malhotra drug development Green Chemistry Process Validation
Submitted by pharmamanufacturing on Fri, 04/10/2009 - 10:53
From Chemical Engineering Progress, Girish Malhotra presents his prescription for the pharmaceutical industry----QbD, PAT and control all play a key role, and chemical engineers will make it happen. The ultimate goal will be entirely new business models for pharma.
Category: FDA cGxP's FDA and Regulatory Issues Drug Safety Pharmaceutical Patents and Intellectual Property Generic Drugs Ranbaxy
Submitted by pharmamanufacturing on Thu, 10/09/2008 - 12:52
A nice, if brief, Q&A appeared today in India's Business Standard, featuring a conversation with Arun Kumar, CEO of generics maker Strides Arcolab.
Category: The Pharma Industry Personalized Medicine New Drug Pipeline and R&D Information Technology and Software Pharmaceutical Patents and Intellectual Property Pharmaceutical Industry CEOs Pharmaceutical Industry Goodwill and Philanthropy Environmental issues and green pharma Supply Chain Management management Drug pricing drug development DIA IBM Life Sciences patient-centered healthcare pandemic monitoring and surveillance Mike Svinte
Submitted by pharmamanufacturing on Wed, 06/25/2008 - 11:11
At a meeting at DIA in Boston yesterday, Mike Svinte, President of Global Life Sciences at IBM provided a sneak peek and insights into a new report probing CEO challenges and concerns and their implications. The report, which is due to be released next month, will distill interviews with more...
Category: The Pharma Industry Pharmaceutical Patents and Intellectual Property Biotechnology and biopharmaceuticals Pharmaceutical Industry Videos
Submitted by pharmamanufacturing on Wed, 04/18/2007 - 13:58
This afternoon, the Senate will vote on sweeping patent reform measures that are pleasing tech companies but worrying pharma and biopharma (more on this from the Houston Chronicle). Read a report The Department of Justice and FTC released a comprehensive report on the subject this morning, while Bloomberg's Washington correspondent...